The European Medicines Agency (EMA) has listed Guillan-Barre syndrome as a ‘very rare’ side effect of the AstraZeneca Covid-19 vaccine.
A total of 833 cases of the neurological disorder, which can cause temporary paralysis and breathing difficulties, were reported worldwide from approximately 592 million doses of the AstraZeneca vaccine that were administered, according to the EMA.
The EMA stated that as a result, Guillain-Barre syndrome should be added as a side effect of the vaccine, occurring in under one in 10,000 people.
Affecting an estimated 3,000 to 6,000 people each year in the United States, most people go on to recover from the disorder.
The disorder was also listed as a side effect of the single-dose J&J vaccine back in July, however, J&J use the same adenovirus technology as AstraZeneca.
Back in July, the US Food and Drug Administration warned of an increased risk of developing the disorder with the J&J vaccine.
However, both regulators have stressed that the vaccine’s benefits outweigh the risks.
IMAGE SOURCE – “AstraZeneca introduces new safe vaccine” (CC BY 2.0) by wuestenigel